Soleno Therapeutics, Inc. — Earnings Quality Grade A
SLNO · Healthcare
Strong financial health
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Insufficient data
Expense Quality
Insufficient data
Insufficient data
SG&A/Gross Profit = 70.4%, exceeds 70%
Insufficient data
Cash Flow Quality
CFFO/NI = 2.24. Profits backed by cash
FCF $0.0B, FCF/NI = 2.24
Accruals ratio = -4.6%. Low accruals
Cash $0.3B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
Debt/EBITDA = 1.9x. Healthy
Insufficient data
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -29% YoY. Normal
Manipulation Score
Calculation error: float division by zero
Portfolio monitoring
Monitor SLNO continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25